Efficacy and safety of using DAAs to treatment the special populations with chronic hepatitis C
- Author:
ZHONG Si-qi
;
FAN Jing-hua
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis C;
direct-acting antiviral agents;
special populations
- From:
China Tropical Medicine
2022;22(09):890-
- CountryChina
- Language:Chinese
-
Abstract:
Abstract:Chronic hepatitis C (CHC) is a global health problem, which is prevalent all over the world. China is a low epidemic area. Hepatitis C virus (HCV) is mainly transmitted through blood, and nowadays, intravenous drug addicts are the key population for the prevention and treatment of hepatitis C. HCV has multiple genotypes and gene subtypes, and the distribution of these genotypes and gene subtypes varies significantly among the regions of the world. Nowadays, the treatment of hepatitis C has entered the era of direct-acting antiviral agents, which have high efficacy and safety in the general population. However, when special populations use direct-acting antiviral agents to treatment hepatitis C, we don't know how its efficacy and safety will be. The special populations include children, adolescents, drug users, HCV/HBV co-infected patients, HCV/HIV co-infected patients, and patients who have comorbidity of HCV and chronic kidney disease. This review will discuss the efficacy and safety of using direct-acting antiviral agents to treat hepatitis C in these special populations.
- Full text:20. Efficacy and safety of using DAAs to treatment the special populations with chronic hepatitis C.pdf
